KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nektar Therapeutics (NKTR) Liabilities and Shareholders Equity (2016 - 2025)

Nektar Therapeutics (NKTR) has 16 years of Liabilities and Shareholders Equity data on record, last reported at $301.3 million in Q3 2025.

  • For Q3 2025, Liabilities and Shareholders Equity fell 2.15% year-over-year to $301.3 million; the TTM value through Sep 2025 reached $1.1 billion, down 26.04%, while the annual FY2024 figure was $303.8 million, 23.66% down from the prior year.
  • Liabilities and Shareholders Equity reached $301.3 million in Q3 2025 per NKTR's latest filing, up from $207.5 million in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $1.5 billion in Q1 2021 and bottomed at $207.5 million in Q2 2025.
  • Average Liabilities and Shareholders Equity over 5 years is $663.8 million, with a median of $494.3 million recorded in 2023.
  • Peak YoY movement for Liabilities and Shareholders Equity: plummeted 45.15% in 2023, then fell 2.15% in 2025.
  • A 5-year view of Liabilities and Shareholders Equity shows it stood at $1.1 billion in 2021, then tumbled by 36.39% to $710.6 million in 2022, then crashed by 43.99% to $398.0 million in 2023, then decreased by 23.66% to $303.8 million in 2024, then fell by 0.82% to $301.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for Liabilities and Shareholders Equity were $301.3 million in Q3 2025, $207.5 million in Q2 2025, and $256.2 million in Q1 2025.